Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted ...
UK biotech Engitix has raised a $25 million series A extension from existing investor Netherton Investments, investing on behalf of BlueCrest Capital Management co-founder Mike Platt. The funding will ...
Senescence. It’s a beautiful-sounding word whose tones suggest it should be a perfume or an essential oil. But that’s not ...
News-Medical.Net on MSN
Remodeling the tumor microenvironment to unlock CAR-T cell potential
Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback